Positively Positive – Living with HIV/AIDS:
HIV/AIDS News
HIV, AIDS and Infectious Disease News
from around the world
Worldwide 91.4 million people have been infected with HIV.
Worldwide 44.1 million people with HIV have died.
Worldwide, 40.8 million people were living with HIV at the end of 2024.
.
Practicing Safe Sex is our best resource in preventing HIV infection through sexual contact.
Sexual contact accounts for 95 percent of all new HIV infections worldwide.
Safe Sex = Disease Prevention – STAY SAFE!
Use A Condom Every Time!
“HIV needs to be in the media each and every day as most people only see snippets of news and these are not effective enough. For this reason, in 2007, I decided to include an HIV/AIDS News page where people could find information on many HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) related issues, Infectious Disease,
and more.
I collaborate with individuals, groups, and organizations throughout the world, to include their HIV/AIDS news articles, press releases, events, workshops, conferences, and more on PositivelyPositive.ca. News items stay on the HIV/AIDS News page for a month,
and then News items go into the HIV/AIDS News Archives.”
Bradford McIntyre
Snapshots of an Epidemic: An HIV/AIDS Timeline
September 25, 2026 - amfAR, The Foundation for AIDS Research - amfAR traces key milestones in HIV/AIDS and the organization’s history, highlighting breakthroughs and challenges in the fight to end the epidemic.
Read more...
Sen. Collins Urges Administration to Spend Global Health Programs Funding
Washington, D.C. – September 24, 2026 - United States Senate Committee on Appropriations - U.S. Senator Susan Collins (R-ME), Chair of the Appropriations Committee, sent a letter to Marco Rubio, Secretary of State, Russell Vought, Director of the Office of Management and Budget (OMB), and Eric Ueland, Chief Operating Officer and Performing the Duties of Administrator of the U.S. Agency for International Development (USAID), asking them to ensure the remaining Global Health Programs funding is spent, citing lifesaving programs.
British Columbia study finds sex differences in the health of people living with HIV
September 24, 2026 - By Sean R. Hosein - Canadian AIDS Treatment Information Exchange (CATIE) - A B.C. study compared health indicators among people with HIV based on sex assigned at birth
At ages 20 and 40, those assigned male at birth had more years free from comorbidities
Researchers noted higher substance use among study participants assigned female at birth
HIV treatment (antiretroviral therapy, ART) has had a tremendous impact on the survival of people with HIV. Researchers increasingly expect that many people taking ART can have a life expectancy approaching that of their peers without HIV. However, this rosy forecast may not apply to all populations. For instance, a study in British Columbia of people with HIV found that between 2012 and 2020, those assigned male at birth had eight more years of life expectancy than those assigned female at birth. This difference occurred despite the availability of universal healthcare and subsidized access to ART.
California’s Prop 38 Immunotherapy Bond Promises Almost Nothing for HIV/AIDS
September 24, 2026 - By Joyce Mitchell - POZ - “No on Prop 38!” urges AIDS activist Joyce Mitchell, noting that the November ballot item seeks $8.4 billion for immunology treatment and cure research—but excludes HIV.
California’s Proposition 38 is asking for $8.4 billion in general obligation bonds to fund research in immunology and immunotherapy, which show promise for developing treatments and cures for numerous diseases. So why is it essentially excluding HIV/AIDS? The pandemic has a total global death toll of more than 44 million people. Immunotherapy research could promote finding a cure plus help people living with HIV.
Nearly 145,000 people in California are HIV positive. They face a significantly higher risk of developing cardiovascular disease and certain types of cancer compared to the general population. There is no cure for HIV/AIDS. And the national political climate is not helping.
Read more...
Lambda Legal and National HIV Advocates Take Trump Administration Restrictions on Transgender HIV Care to Trial
September 23, 2026 - LAMBDA LEGAL - When care is withheld for political reasons, patients stop trusting their providers. When trust breaks, they stop showing up for the treatment that keeps them alive.
Today, Lambda Legal and Herbert Smith Freehills Kramer (US) LLP presented their case at a bench trial in American Academy for HIV Medicine, et al. v. HRSA, et al., the lawsuit challenging the Trump Administration’s efforts to exclude transgender patients living with HIV from the Ryan White HIV/AIDS Program and restrict the use of Ryan White funds when providing HIV care and other care for these patients. The case was brought on behalf of the American Academy of HIV Medicine (AAHIVM), the HIV Medicine Association (HIVMA), the International Association of Providers of AIDS Care (IAPAC), and individual provider plaintiffs.
The Ryan White Program was built to provide integrated care for low-income people living with HIV, a population that includes a significant number of transgender people. Under the funding conditions at issue, Ryan White funding recipients cannot acknowledge or respect the identities of their transgender patients and cannot use program funds in ways that necessitate them doing so, such as by treating co-occurring conditions like gender dysphoria through gender-affirming hormones. That leaves transgender patients cut off from care Congress built this program to give them.
WHAT REMAINS AT THE END: on cimbing, living with aids, and survival
September 23, 2026 - By Gregory Fowler - WHAT REMAINS AT THE END: on climbing, living with aids, and survival is Gregory Fowler’s memoir of surviving the darkest years of the AIDS epidemic and discovering in the mountains a reason to keep moving forward.
Infectious disease epidemics are associated with global losses in human resources for health, with low- and middle-income countries impacted relatively more, according to analysis over 20 years and 194 countries
September 22, 2026) - PLOS Medicine - Global, regional, and national impact of epidemic disasters on health workforce equality between 1990 and 2019: An ecological and modeling study
Ottawa scientists explore the use of long-acting cabotegravir + rilpivirine in pregnancy
September 22, 2026 - By Sean R. Hosein - Canadian AIDS Treatment Information Exchange (CATIE) - Long-acting HIV treatment with cabotegravir + rilpivirine is an option for some people
International guidelines do not recommend its use during pregnancy due to efficacy concerns
Researchers found promising results in pregnancy when oral therapy alone was not an option
Long-acting formulations of cabotegravir + rilpivirine—a combination sold as Cabenuva in Canada and several other high-income countries—have proven effective in the treatment of people with HIV. These long-acting formulations are injected deep into the buttocks every two months. Cabenuva is generally well tolerated, though some people report temporary discomfort and pain at the injection site.
According to a team of scientists at the Ottawa Hospital, leading international guidelines generally recommend the use of Cabenuva but do not recommend its use during pregnancy or in people who are trying to become pregnant. This is because during the later stages of pregnancy, physiological changes may reduce the concentration of cabotegravir + rilpivirine in the blood. In theory, this could reduce the effectiveness of treatment for the parent and potentially increase the risk of HIV transmission to the fetus.
Watch: New Irish short film highlights the everyday reality of living with HIV
22 September, 2026 - By Ciara Kelly - GCN Magazine - My Day Is The Same As Yours is now available to watch on the Sexual Health Centre YouTube channel.
My Day Is The Same As Yours is a new short film available on YouTube that provides insight into the everyday reality of living with HIV. Produced by the Cork-based Sexual Health Centre, it is directed by their HIV Programme Manager Ian Brennan and filmmaker Jack Deacon, and stars LGBTQ+ Support Worker Gabriel Marttin de França.
Read more...
Global Virus Network Statement on H5N1 Detections in Australian Mammals
TAMPA, FL, USA (September 18, 2026) - Global Virus Network (GVN) - Latest detection in an endangered Australian sea lion follows infections in fur seals, a dolphin and foxes
The Global Virus Network (GVN) is closely monitoring detections of highly pathogenic avian influenza A (H5N1), commonly known as bird flu, in several mammal species in Australia as the virus continues to spread among birds and mammals worldwide.
On Sept. 13, Australian authorities confirmed the first detection in an Australian sea lion, an endangered species, at Seal Bay on Kangaroo Island. Australia reported its first confirmed detection in a mammal on Aug. 23, when a long-nosed fur seal found at Beachport in South Australia tested positive. A second long-nosed fur seal near Kangaroo Island was confirmed two days later. Subsequent detections included a red fox in metropolitan Adelaide, a common dolphin at Goolwa and a second fox at Normanville.
Scenes From the 2026 U.S. HIV/AIDS Conference in Anaheim, California
September 18, 2026 - By Trent Straube - POZ - The theme of #2026USCHA is “United and Unbreakable: The HIV Movement at 45.” It marks “our commitment to the future.”
The HIV community is gathering for its largest annual event—and here’s your virtual front row seat to the inspiring speeches, informative workshops, exhibit hall booths and all-around joyous spirit. The U.S. HIV/AIDS Conference (USCHA) is taking place from September 17 to 20 in Anaheim, California.
Read more...
Teaching the immune system to control HIV
TAMPA, FL, USA (September 18, 2026) - Global Virus Network (GVN) - There is no cure for HIV. While scientists have made considerable progress in controlling the infection, patients still must take daily antiretroviral medication for the rest of their lives. Results from a clinical trial led by Rockefeller, Imperial College London, and the University of Oxford (RIO) have offered a new strategy, suggesting that just one or two doses of broadly neutralizing antibodies (bNAbs) can suppress the virus long-term, keeping it at undetectable levels for months and even years.
Now data from the RIO trial reveals how the bNAbs used kept the virus in check, with lessons that may inform HIV therapy. In a paper published in Nature Medicine, researchers found that participants who already had their own neutralizing antibodies against HIV were better able to control the virus, suggesting that a patient’s natural immune response can work alongside bNAbs. The bNAbs also appear to have accelerated the decline of the intact viral reservoir, the pool of dormant HIV that can reignite infection when treatment stops.
AIDS Walk 2026: 40th Anniversary
September 16, 2026 - Ribbon Community - Join us Friday, September 18
3:00 PM – Gather to walk in the parking lot behind the Sunset Beach concession stand
4:00 PM – Reflection at the AIDS Memorial
5:30 PM – Show and Community Panel at The Junction (1138 Davie St.)
Ribbon Community is thrilled to host this year’s 40th anniversary AIDS Walk on Friday, September 18. It’s a free community event about the past, present, and future of the HIV response, and everyone is welcome. Thanks to generous sponsorship from ViiV Healthcare, this event is free!
Rethink, Rebuild, Rise
This year, the AIDS Walk will focus on honouring and celebrating the past, present, and future of the HIV response, and the ways our communities continue to connect amid HIV, HIV stigma, and the underlying and reinforcing inequities. Pulling from the 2026 World AIDS Day theme of Rethink, Rebuild, Rise, this community celebration will be an opportunity to continue the important work of HIV activists globally throughout 40+ years.
Global Fund Report Shows Countries Fought to Protect Essential Health Services Despite Challenging Year
GENEVA – 16 September 2026 - The Global Fund - The Global Fund partnership has now helped save 72 million lives since 2002, with this year’s Results Report highlighting how country and community leadership, innovation and partnership helped protect essential services and safeguard decades of progress against HIV, tuberculosis (TB) and malaria amid unprecedented global health challenges.
Countries and partners showed remarkable resilience in the fight against HIV, TB and malaria in 2025, as they worked together to protect hard-won gains during one of the toughest periods in global health, according to the Global Fund’s 2026 Results Report released today.
Across more than 100 countries where the Global Fund invests, governments, communities, civil society and bilateral and multilateral partners adapted to mounting pressures – from sharp cuts in international funding to conflict, displacement and growing humanitarian need – to sustain essential services and protect more than two decades of progress against the three diseases. The Global Fund partnership worked alongside countries to address critical gaps, sustain essential programs and accelerate access to innovation.
Fiji declares HIV emergency as 1 in 60 Fijian adults live with HIV
September 16, 2026 - RNZ Pacific Reporters - Radio New Zealand - Fiji’s Health Minister Dr Atonio Lalabalavu has formally declared a national HIV emergency in the country.
In a pre-recorded video press statement on Tuesday, Dr Lalabalavu said the decision was backed by Prime Minister Sitiveni Rabuka and his Cabinet due to the “seriousness of the epidemic”.
Read more...
Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.
September 15, 2026 - DURHAM, N.C.--(BUSINESS WIRE)-- ViiV Healthcare. - Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare announced it has funded 230 community-based organizations this year to strengthen essential HIV services and help connect people to HIV prevention and care
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced more than $33 million in U.S. community grants awarded in 2026. These investments support 230 community-based organizations in 110 cities across 36 states and territories, including Puerto Rico, working to ensure that people and communities most disproportionately impacted by HIV have access to the support they need.
Weill Cornell Medicine Receives $3 Million to Launch Research Center Focused on HIV’s Effects on the Brain
September 14, 2026 - Weill Cornell Medicine - Weill Cornell Medicine and Rutgers Health in New Brunswick have received a four-year, $3 million grant from the National Institute of Mental Health (NIMH) to build the infrastructure and resources that will accelerate discoveries about HIV-associated brain injury. The New York-New Jersey Center for Actionable NeuroHIV Biomarkers (NYJ-CAN-BIO) will provide the expertise, training and latest technologies needed to understand how HIV impacts the brain. This research center could uncover molecular markers that enable new diagnostics and lead to potential therapies for people living with neurological complications related to HIV.
Full Fourth Circuit hashes Pentagon ban on HIV-positive enlistees
RICHMOND, Va. - September 14, 2026 - By Joe Dodson - Courthouse News Service - The military argues the ban is rational to limit costs and maintain diplomatic peace with other countries, while the plaintiffs argue it fails to reflect modern science.
The entire Fourth Circuit heard a challenge to the military’s ban on HIV-positive service members Monday after a three-judge panel of the federal appeals court greenlit the policy in February.
The plaintiffs include a trans woman who was honorably discharged from the Army for being HIV-positive, a gay man who was in the Georgia National Guard but cannot join the Army, and a cisgender woman who cannot enlist in the Army because she has HIV, along with the advocacy organization Minority Veterans of America. They argue the policy, which prohibits even those whose treatment renders the virus undetectable, is discriminatory and not rooted in science.
HIV and AIDS: Detection, Prevention, and Treatment
Newswise - 14-Sep-2026 - UT Health Houston - About 1.2 million people in the United States are living with HIV, or human immunodeficiency virus. Because of major advances in medical treatment and technology, people with HIV are living long, healthy lives.
Here’s what to know about the condition ahead of HIV/AIDS and Aging Awareness Day, observed Sept. 18.
Kelly Dooley’s TB research receives MERIT Award from the NIH
September 11, 2026 - By Paul Govern - Vanderbilt Health News - Vanderbilt University Medical Center - Researchers must continually chase funding for their work. Kelly Dooley’s prestigious award from the NIH is intended to help provide respite from that chase.
Kelly Dooley, MD, PhD, MPH, Addison B. Scoville Jr. Professor of Medicine and director of the Division of Infectious Diseases at Vanderbilt University Medical Center, has received a MERIT Award (Method to Extend Research in Time Award) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
According to the NIH, MERIT Awards provide long-term grant support to investigators “whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner.”
Despite declining HIV diagnoses, barriers to testing and prevention persist in Peel
September 11, 2026 - By Bridget Potasky - Brampton Guardian - Despite a recent decline in HIV diagnosis rates, marginalized communities in Peel continue to face barriers to HIV prevention including stigma, language differences, and affordability issues.
HIV diagnosis rates in Peel Region may be declining after rising sharply in 2023, but some residents continue to face obstacles to accessing HIV testing and prevention care.
Read more...
Hannah Stadtler completes her Ph.D. with a mission to understand HIV and the brain
September 11, 2026 - By Christopher Richmond - VCU News - Virginia Commonwealth University - Her research was propelled by a Wright Center biomedical sciences initiative, and her M.D. is next as she continues in VCU’s Medical Scientist Training Program.
Hannah Stadtler knew whom she wanted to work with before even arriving at VCU.
Without having set foot on campus, she had cold-emailed Gretchen Neigh, Ph.D., a professor in the Virginia Commonwealth University School of Medicine’s Department of Neuroscience and Anatomy. Neigh’s work at the intersection of stress and biology aligned exactly with where Stadtler wanted to take her science.
Feds announce $5M for HIV self-test kits, more peer support staff
September 10, 2026- By Brittany Hobson - The Canadian Press - CBC - Manitoba declared public health emergency over HIV rates in May
The federal government announced $5 million in funding for HIV prevention and support services at a news conference in Winnipeg on Thursday.
Doug Eyolfson, a Manitoba member of Parliament, made the announcement with Dr. Joss Reimer, Canada's chief public health officer.
Listen & Read more...
Government of Canada expands access to HIV self-testing and peer support services
September 10, 2026 - Winnipeg, MB - Public Health Agency of Canada - Approximately 2,300 new HIV diagnoses were reported in 2024, and an estimated 7,000 people living with HIV are unaware of their status. Knowing one’s HIV status is the first step to prevention, treatment, and care – and with treatment, people with HIV can live long, healthy lives.
Today, on behalf of the Honourable Marjorie Michel, Minister of Health, Doug Eyolfson, Member of Parliament for Winnipeg West, alongside the Chief Public Health Officer of Canada, Dr. Joss Reimer, announced a $5 million investment to improve HIV prevention and support services. This funding will increase access to HIV self-test kits and support the hiring of peer-based support workers for populations facing the highest burdens of HIV and barriers to care across the country.
What to Know About the New HIV Medication Bixlenvo
Sept. 10, 2026 - By Tim Murphy - TheBody - On Aug. 27, the U.S. Food and Drug Administration (FDA) approved Bixlenvo, a new one-pill-daily HIV regimen. It’s made up of two drugs:
Read more...
The Wistar Institute Wins $15M+ NIH Investment to Advance HIV Cure Research Strategies
PHILADELPHIA — (Sept. 9, 2026) The Wistar Institute -Grants funding positions Philadelphia as an anchor for HIV cure research—advancing combination strategies aimed at durable, drug-free remission.
More than 40 million people worldwide live with HIV and depend on daily antiretroviral therapy to stay alive. Federal funding is a major driver advancing the research needed to develop new therapy strategies toward a cure. Today, The Wistar Institute announces the National Institutes of Health (NIH) has awarded two major grants totaling more than $15M to Luis J. Montaner, D.V.M., D.Phil., director of Wistar’s HIV Cure and Viral Diseases Center.
One award is a 2-year, $11.2 million award to the BEAT-HIV Martin Delaney Collaboratory (BEAT-HIV.org), a leading consortium of top U.S. researchers codirected by Montaner, executive vice president and Herbert Kean, M.D., Family Professor; James L. Riley, Ph.D., professor at Perelman School of Medicine at the University of Pennsylvania; and Robert F. Siliciano, M.D., Ph.D., professor at Johns Hopkins University School of Medicine. Building on five-year grants awarded in 2016 and 2021, the new funding extends support through 2028.
Scientists study computer simulation of implementing over-the-counter HIV pre-exposure prophylaxis
SEPTEMBER 8, 2026 - By Sean R. Hosein - Canadian AIDS Treatment Information Exchange (CATIE) - Scientists in the U.S. modelled the potential effects of making PrEP available over the counter
Increasing PrEP use by 50% would result in a 15% decrease in new HIV transmissions
The model also estimated risks of over-the-counter access on kidney injury and drug resistance
In clinical trials and demonstration projects, HIV pre-exposure prophylaxis (PrEP) is highly effective at reducing the risk for HIV infection.
The most widely used formulation of PrEP is TDF + FTC, chiefly because of its relatively low cost.
Significantly reducing new HIV infections will likely require increased access to HIV testing, PrEP and retention in PrEP care.
US HIV cash cuts: Thousands at risk
7 September 2026- By Tracy Tafirenyika - The Nambian - The United States’ decision to phase out HIV funding to Namibia leaves over 29 000 Namibians facing the loss of critical support services.
The Ministry of International Relations and Trade released a statement last week, saying US support would transition from financial assistance to technical cooperation over the next year.
Read more...
Trump administration ends $45M support for Namibia HIV program
09/05/26 - By Mira Bhakta - THE HILL- The Trump administration announced it will be ending its financial support for Namibia’s HIV response program, following a little more than two decades of annual payments — totaling more than $1.1 billion.
The U.S. will provide its final $45 million payment in fiscal 2027 as “this support will transition into a technical cooperation model,” the U.S. Embassy in Namibia and Namibia’s Ministry of International Relations and Trade said in a joint statement released Friday.
Read more...
UConn Professor Takes on HIV/AIDS Denialists Yet Again
September 4, 2026 - By Kimberly Phillips - UConn Today - UConn University of Connecticut - Kalichman talked with UConn Today about AIDS denialism, his recent research, and where we go from here
These days, Seth Kalichman takes note of the lack of headlines about HIV and AIDS, especially as compared to the number of stories that dotted front pages in the 1980s and 1990s.
“It’s what we were all working for,” says Kalichman, a professor of psychological sciences at UConn. “It’s just not the same crisis that it once was. It’s still a personal crisis for every individual who contracts HIV infection, but in terms of being the same public health crisis, we’re past those days thanks to the success of HIV treatments.”
What is a problem today, he says, is the growing number of AIDS denialists and their efforts to undo those successes.
‘We finally understand what we have to do’: antibody studies point the way to an HIV cure
4 September 2026 - By Gus Cairns - aidsmap - The 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, featured few new scientific breakthroughs in terms of vaccines or cures for HIV. But as well as featuring two more cases of cure following stem-cell transplants, a range of studies were presented that shed new light on how we might achieve a less drastic and more accessible form of cure, or at least enable people not to have to take regular antiretroviral therapy (ART).
Read more...
Threats to infectious diseases research leave our country at significant risk
September 3, 2026 - IDSA - Infectious Diseases Society of America - IDSA and HIVMA are concerned by a notice released Aug. 28 by the National Institutes of Health announcing a proposed overhaul of the National Institute of Allergy and Infectious Diseases’ clinical research program with few details and a brief comment period. Changes of the magnitude suggested deserve a lengthier and meaningful opportunity for input from researchers, clinicians, community partners and other stakeholders including Congress.
The proposed restructuring comes after many months of delays in NIH issuing renewal notices for NIAID’s clinical trial networks and Centers for AIDS Research, whose discoveries helped establish the United States as a leader in biomedical research worldwide. The renewal notices for the ID networks were finally released this week, but ongoing delays in the renewals for the pioneering CFARs and HIV clinical trial networks are alarming.
Cancer medication helps reduce SIV reservoir, increases hope for HIV cure
September 3, 2026 - Emory Health Sciences - Emory University researchers have provided the first proof-of-concept in a nonhuman primate model for eliminating HIV-infected cells with venetoclax, a clinically approved medication for cancer. Venetoclax effectively targets and blocks Bcl-2, a protein that not only regulates whether cells live or die but also promotes the survival of cancer cells. Similarly, Bcl-2 is a culprit in sustaining HIV cell reservoirs. The research team determined venetoclax is also effective at reducing simian immunodeficiency virus (SIV) reservoir levels in vivo when given as part of a combination treatment for HIV.
The study results are reported in Nature Microbiology, and two clinical trials are under way to test venetoclax in people living with HIV.
Trailblazing D.C. Faith, Nightlife, and HIV/AIDS Leader Bishop Rainey Cheeks Is Remembered by Those Who Loved Him
Sep 3, 2026 - By Tim Murphy - TheBody - On Aug. 11, the U.S. lost one of its longtime pillars of both the HIV/AIDS and Black queer communities: Bishop Kwabena Albert “Rainey” Cheeks, who was 74. He not only co-founded the seminal, Washington, D.C.–based HIV service organization Us Helping Us (in 1985) but also co-ran the legendary D.C. nightclub The ClubHouse (from 1975 to 1990) and founded and led the city’s LGBTQ-affirming Inner Light Ministries church (from 1993 to 2022).
Read more...
Sexual Health Is Health: Testing, Treatment and Prevention for All, says AHF
LOS ANGELES--(BUSINESS WIRE)-- Sep 3, 2026 - AIDS Healthcare Foundation (AHF) -As sexually transmitted infections continue to rise worldwide, AIDS Healthcare Foundation (AHF) marks World Sexual Health Day by calling on governments and health systems to expand access to prevention, testing, and treatment services for HIV and other STIs.
Despite proven tools to prevent, diagnose, and treat HIV and other STIs, gaps in access continue to put millions of people at risk globally. With an estimated 1.2 million new HIV infections each year globally, more than 1 million STIs acquired every day worldwide, and an estimated 374 million new cases of syphilis, chlamydia, gonorrhea, and trichomoniasis each year, the time to act is now. Declining global health funding and reduced access to condoms and routine screening threaten to further fuel rising STI rates.
Syphilis alone accounts for an estimated 8 million of those new cases annually and often causes no visible symptoms, allowing the infection to spread undetected.
Scientists are developing on-target HIV vaccines to avoid unhelpful immune responses
3 September 2026 - By Gus Cairns - aidsmap - Several studies presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro last month dealt with vaccines designed to counteract a phenomenon that has limited their efficacy in the past – immunodominance.
Immunodominance is the immune system’s tendency to focus on the most conspicuous parts of a virus. With HIV, those parts act like decoys: they vary freely from one virus to the next, so antibodies against them work on few other strains.
Read more...
Nobody Told Us We Would Grow Old
September 2, 2026 - By Eric Novak - Still Here at Seventy — Aging with HIV
When I was diagnosed in 1984, nobody talked about growing old with HIV. The conversation was about survival — immediate, urgent, and often measured in months rather than years. Medical advice was less about long-term planning and more about settling affairs.
I am now seventy years old. I have lived with HIV for more than four decades.
What that means medically, psychologically, and practically is something nobody fully prepared me for — because nobody expected any of us to get here.
Namibia Rejects US Demands for Data and Pathogen-Sharing
02/09/2026 - By Kerry Cullinan - Health Policy Watch - Namibia has rejected the United States’ demands for sharing health data and pathogen information during negotiations for renewed US support for its HIV programme, according to The Namibian newspaper.
In the past few years, the country has received around $45 million a year in support from the US President &rsquo: Emergency Plan for AIDS Relief (PEPFAR), and a total of over $1 billion since 2003.
Read more...
Recurring escape routes reveal patterns in HIV evolution
September 1, 2026 - By T Vasanthakumar - Fred Hutchinson Cancer Center - From the Cohn Lab, Vaccine and Infectious Disease Division
Within each person living with HIV, viral evolution unfolds at a remarkable pace. As the virus replicates, it rapidly accumulates mutations, generating thousands of genetically distinct viral variants. That extraordinary diversity has long complicated efforts to vaccinate against and cure HIV.
Despite HIV’s immense diversity, some antibodies can recognize and neutralize a broad range of viral variants. These broadly neutralizing antibodies (bNAbs) have emerged as promising tools for both HIV treatment and prevention. But even bNAbs can eventually be outpaced by HIV’s rapid evolution. Mutations can subtly reshape the virus, allowing HIV to escape recognition by bNAbs while retaining its ability to infect cells.
Scientists have long known that HIV can become resistant to antibody therapies. What has been harder to track is exactly how that escape unfolds.
How HIV Affects the Eyes of Aging Adults
August 31, 2026 - By Tayler Shaw - University of Colorado Anschutz - CU Anschutz ophthalmic epidemiologist Alison Abraham, PhD, MS, MHS, led a study that suggests adults aging with well-controlled HIV have a higher prevalence of some eye conditions, namely dry eye.
Older adults with well-controlled HIV may have a higher prevalence of certain eye conditions, particularly dry eye, compared to similar adults without HIV, according to a novel study led by a University of Colorado Anschutz Department of Ophthalmology faculty member.
The study is the first to comprehensively describe eye health in adults aged 60 and older who are living with durably suppressed HIV (meaning a person’s viral load is low and they cannot sexually transmit HIV to others) compared to similarly aged adults who do not have HIV, explains Alison Abraham, PhD, MS, MHS, the lead author.
Society for AIDS in Africa invites African countries to bid for 2029 ICASA conference
31 August 26 - By Francis Ameyibor II - Modern Ghana - The Society for AIDS in Africa (SAA) has opened the bidding process for African countries interested in hosting the 25th International Conference on AIDS and STIs in Africa (ICASA 2029).
The SAA said any African country that meets the prescribed qualification criteria is eligible to submit a bid to host the conference in 2029.
In a statement issued by the SAA President, Dr Nchabi Richard Kamwi, African countries interested in hosting ICASA 2029 were invited to submit their application documents to the SAA Secretariat in Accra.
The new deadline for submission of applications is Friday, October 30, 2026, the statement obtained by Modern Ghana News in Accra on Monday said.
Semen facilitates infection with Monkeypox virus
FRANKFURT - August 30, 2026 - Goethe University Frankfurt - Study by Goethe University and Universitätsmedizin Frankfurt: Fibrous proteins in seminal fluid facilitate viral uptake
Monkeypox virus used to be transmitted predominantly from animals to humans. In recent years, however, new virus variants have become increasingly capable of spreading from person to person. Researchers at Goethe University and Universitätsmedizin Frankfurt have now found that seminal fluid facilitates the uptake of monkeypox virus into cells.
The World Health Organization (WHO) has declared a public health emergency of international concern twice in recent years because of mpox outbreaks, most recently in 2024. In fact, infections with the monkeypox virus are comparatively rare. However, in 2023, a virus variant emerged that infected around 100,000 people in several African countries in the first half of 2024 alone and killed more than 200, primarily children and immunocompromised individuals. There have also been infections in Europe and Asia, and new mpox cases continue to occur in Germany to this day, albeit at a low level.
HIV/AIDS In Vietnam: Vulnerable Communities Access Care
August 30, 2026 - By Daniela Escobar - The Borgen Project - Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and poverty are closely connected. In Vietnam, significant progress has been made in reducing poverty over the last few years. The number of people living on less than $1.90 a day fell from 37% in 2002 to 1.8% in 2018, and about 10 million people moved out of poverty between 2010 and 2020. However, that progress has not reached everyone equally.
Poverty remains a serious issue for ethnic minority communities, farming families and people living in rural and remote areas, especially in the Midlands and Northern Mountains and the Central Highlands. Many in these communities continue to struggle with low incomes and limited access to education, health care and jobs.
Why STIs persist—and how to protect your health
August 27, 2026 - By Irene Stafford - UT Health Houston News - UT Health Houston - Ask the Expert
Welcome to “Ask the Expert,” a UTHealth Houston news series where our leading experts examine pressing health challenges. In this edition, we discuss sexually transmitted infections (STIs), why they remain so common among teenagers and young adults, and how simple steps can help protect your health.
For many adolescents and young adults, life revolves around new experiences, greater independence, and new relationships. It’s also a time when sexual health becomes more important than ever. Yet conversations about sexually transmitted infections (STIs) can still feel uncomfortable or embarrassing. The truth is, they shouldn’t.
Billy Porter Set to Receive Legacy Award From Elizabeth Taylor AIDS Foundation
August 27, 2026 - By Chris Gardner - THE HOLLYWOOD REPORTER - The Emmy Award-winning actor will headline a Sept. 17 program that will feature Vanity Fair taking home a trophy, CNN’s Laura Coates hosting the whole affair and Debra Cox hitting the stage.
The Elizabeth Taylor AIDS Foundation is finalizing the program for its Los Angeles fundraiser, a Night of Compassion, by drafting Billy Porter to receive one of the top awards.
Listen & read more...
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
FOSTER CITY, Calif.--(BUSINESS WIRE)-- August 27, 2026 - Gilead - Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals -
- Bixlenvo Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens -
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.
This novel HIV treatment pairs bictegravir, a global guideline-recommended integrase strand transfer inhibitor (INSTI) with a high barrier to resistance, with lenacapavir, a first-in-class capsid inhibitor that has a novel mechanism of action with no cross-resistance to other antiretrovirals.
Addressing HIV/AIDS in Timor-Leste
August 27, 2026 - By Adebisi Aliyah Adeola - The Borgen Project - Although HIV/AIDS in Timor-Leste remains relatively uncommon compared with many countries in the region, it remains an important public health concern. Timor-Leste has a low-level HIV epidemic, but new cases continue to be identified among the general population, including people attending antenatal, sexually transmitted infection and tuberculosis clinics. Limited access to HIV testing, stigma surrounding the disease and gaps in rural health care continue to challenge prevention and treatment efforts. While the country’s HIV epidemic remains relatively small, continued investment in prevention, education and treatment is essential to reducing new infections and improving long-term public health.
Sept. 17: Film Screening and Discussion: ‘Gert’s Boys’ and HIV Awareness
August 27, 2026 - The Elm - University of Maryland, Baltimore - Past, Present, and Future: HIV, “Gert’s Boys,” and the AIDS Memorial Quilt
Join us for a screening of the award-winning documentary “Gert’s Boys,” followed by a panel discussion exploring HIV’s ongoing impact on individuals and communities.
Honored with accolades including Festival Favorite and Director’s Choice at the Palm Springs LGBTQ+ Film Festival, as well as the Best Narrative Short Audience Award at the Reel Queer Film Festival, “Gert’s Boys” offers a powerful portrait of resilience, advocacy, and the lived realities of the HIV epidemic.
Why a team researching aspirin’s potential in HIV prevention have shifted to HPV
August 26, 2026 - by Laura Beveridge - The CTN+ | CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research - How a 40-year study in Nairobi, Kenya demonstrates the importance of flexibility in science
Look inside your medicine cabinet, and you’ll likely find a humble bottle of acetylsalicylic acid — better known as aspirin. It’s an over-the-counter anti-inflammatory drug used to treat everything from headaches to fevers, while also lowering stroke risk. Its ubiquity, low cost, and relative safety mean that it’s one of the most widely used medications globally.
But could it be used to prevent HIV?
After much research, the Aspirin Study (CTN 316) team determined that the answer is ‘no’. However, their efforts proved to be about much more than any single result or virus. It demonstrated why the scientific process is often more about the journey than the destination.
New Freddie campaign turns PrEP access in North America into HIV prevention in Africa
August 26, 2026 - By Devon Banfield - NOW Toronto - PrEP Onwards will fund six months of long-acting HIV prevention in Africa for every person who starts PrEP through Freddie in Canada or the U.S.
A new initiative from 2SLGBTQIA+ healthcare platform Freddie is connecting HIV prevention in North America with access to long-acting HIV prevention in Africa, allowing one person’s decision to start PrEP to become an opportunity for someone else to access care.
Read more...
The impact of HIV and antiretroviral therapy on cervical cancer burden in Zambia: a modelling study
August 25, 2026 -- Nature - Abstract
Cervical cancer is the leading cause of cancer death among women in Zambia, where widespread HIV infection elevates cervical cancer risk. However, HIV’s contribution to Zambia’s cervical cancer burden and the extent to which antiretroviral therapy (ART) has mitigated this burden, remain poorly quantified. We adapted HPVsim, an existing open-source mathematical model simulating human papillomavirus (HPV) and cervical cancer natural history, to capture the dual burden of cervical cancer and HIV in Zambian women. We extended HPVsim by incorporating country-specific HIV incidence data and modeled how HIV alters cervical disease progression through CD4 cell count-dependent modification of HPV susceptibility and disease severity. We calibrated the model to GLOBOCAN cervical cancer estimates and cervical cancer incidence rate ratios by HIV status estimated from the Zambian Cancer Registry. We estimated that by 2025, 49.9% of all cervical cancer cases in Zambia could be attributed to HIV co-infection. Although ART prevented at least an estimated 5.4% of cervical cancer cases nationally and 8.7% of cases among women with HIV, HIV remains a major driver of the cervical cancer burden. HIV-stratified prevention strategies will be essential for Zambia to achieve the World Health Organization’s cervical cancer elimination targets.
Community-based HIV services are crucial for Venezuelan migrants in Colombia
25 August 2026 - By Krishen Samuel - aidsmap - Nearly 7% of a large group of Venezuelan migrants in Colombia tested positive for HIV, according to a presentation by José Guillen from Red Somos at the recent 26th International AIDS Conference (AIDS 2026) held in Rio de Janeiro. Most were linked to treatment and were able to achieve viral suppression, despite administrative and legal barriers.
Read more...
Ontario team finds increasing rates of key sexually transmitted and blood-borne infections (STBBIs)
August 25, 2026 - By Sean R. Hosein - Canadian AIDS Treatment Information Exchange (CATIE) - Ontario researchers studied testing trends for sexually transmitted and bloodborne infections
Cases of two infections diagnosed at the same time increased 10% per year from 2013 to 2023
These co-infections were most common in Northwestern Ontario, followed by the Toronto area
Researchers at McMaster University in Hamilton and Public Health Ontario conducted a study of health-related information collected between 2013 and 2023. The researchers focused on rates of testing and diagnoses of the following key sexually transmitted and blood-borne infections (STBBIs)
The researchers reviewed data from 269,814 positive test results; the vast majority were for conditions other than HIV. All infections were confirmed by laboratories in Ontario.
Positively Positive
August 25, 2026 - By Bradford McIntyre - POZ - Bradford McIntyre celebrates 23 years of raising HIV and AIDS awareness through his website and advocacy work.
August 15, 2026, marked the 23rd anniversary of the launch of my website Bradford McIntyre Positively Positive Living with HIV/AIDS. Designed to create awareness about HIV and AIDS and promote positive messages of living with HIV, the website has grown from a 20-page site in 2003 into an internationally recognized information and resource hub. To date, my independent, ad-free website has had more than 21 million visitors from 187 countries.
Antiretroviral therapy important in curbing TB – UCT academic tells Aids conference
August 24, 2026 - University of Cape town - Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV. While antiretroviral therapy (ART) has reduced TB incidence, there remains a substantial TB burden in ART-experienced individuals. Interruptions in HIV treatment significantly increase the risk of tuberculosis, and the risk remains elevated even after treatment is resumed.
Dr Haroon Moolla of the University of Cape Town’s (UCT) Centre for Integrated Data and Epidemiological Research told the recent 26th International AIDS Conference (AIDS 2026), held in Rio De Janeiro, Brazil, that returning to HIV care does not completely undo the impact of treatment interruptions. Preventing interruptions in the first place appears important for reducing TB risk.
‘People Are Dying’: HIV Survivor Sounds Alarm as Global Aid is Cut
August 24, 2026 - By Mya Trujillo - The Washington Informer - Local, International Commitment to Fight HIV and AIDS Remains Strong Despite PEPFAR Losses.
In March 1982, at 21 years old, Gregg Gore was told he had one year to live. He had just been diagnosed with HIV.
During this time, there was no effective medicine to treat HIV, and prolonged, untreated exposure to the immunodeficiency virus developed into AIDS, almost certainly resulting in death. From 1981 to 1990, 100,777 people in the United States were victims of HIV-related deaths, as the first effective antiretroviral agent, zidovudine, wasn’t approved until 1987.
Read more...
Ageing with HIV: global report highlights the need to prepare health systems
August 24, 2026 - Luicer Anne Ingasia Olubayo, University of the Witwatersrand and Francesc Xavier Gomez-Olive Casas, University of the Witwatersrand - The Conversation - The Lancet HIV Commission on Ageing’s 2026 report highlights how profoundly the global HIV epidemic is changing.
In 2025, an estimated 11.5 million (29%) people living with HIV were aged 50 years and older. This is projected to increase to 20.2 million by 2040. That would account for more than half (51%) of all people living with HIV. And, crucially, 96% will live in low- and middle-income countries. Sub-Saharan Africa is continuing to shoulder the greatest burden of the global HIV epidemic.
Much of this change reflects the success of antiretroviral therapy (ART), which has enabled millions of people who acquired HIV earlier in life to grow older. The challenge has gone beyond helping people live longer, to ensuring they age well – that they maintain good health, independence and quality of life throughout older age.
In The Spotlight | What are broadly neutralising antibodies and what do they mean for the fight against HIV?
August 24, 2026 - By Catherine Tomlinson - Spotlight - HIV is known for its ability to outsmart our immune system’s normal defences. A small number of people living with the virus are however able to generate unusually effective immune responses. In this special briefing, we zoom in on broadly neutralising antibodies (bNAbs), the secret sauce in these immune responses, and their potential role in the future of HIV treatment and prevention.
Our immune systems are highly effective at identifying and fighting off foreign invaders, such as viruses. One way our immune systems does this is by producing antibodies. In short, antibodies recognise viruses and then latch on to them. This blocks the viruses from entering our cells and flags them for destruction by other parts of the immune system.
Read more...
R.I.P. Walt Odets, Influential Psychotherapist and Chronicler of HIV and Gay Men
August 21, 2026 - By Eva Lorenz - POZ - Odets “cared deeply about gay men and the challenges of living through the AIDS epidemic.”
A clinical psychologist and author who wrote about HIV and gay men amid the AIDS epidemic, Walt Odets died on July 5, 2026, at his home in Berkeley, California. The cause of death was Alzheimer’s disease, according to the Bay Area Reporter. He was 79.
“During the AIDS crisis, Odets emerged as one of the most influential voices examining the emotional lives of HIV-negative gay men,” wrote Queer Happened Here, a digital archive and visual history project founded by writer and historian Marc Zinaman, in an Instagram post honoring Odets. “While prevention campaigns at the time often relied on fear & shame, he argued that trauma, grief, loneliness, survivor’s guilt, & intimacy had to be understood as central to HIV prevention.”
Read more...
MONSTER MANOR by The Velvet Circus to Benefit HIV/AIDS Medication Fund
Aug. 21, 2026 - By Stephi Wild - Broadway World - The cast includes aerialists Skyy, Kahn and Spinnin Shae alongside drag performer Hanna Barbeara of Camp Wannakiki.
After the first sold-out production, the crew behind The Velvet Circus returns with a new production: “Monster Manor,” Thursday, October 1 at 7 p.m. at The Nunnery (900 Liberace Avenue, Suite A-102).
Read more...
B.C. team forecasts the healthcare needs of people living with HIV in the coming decade
August 21, 2026 - By Sean R. Hosein - Canadian AIDS Treatment Information Exchange (CATIE) - Thanks to effective HIV treatment, the proportion of people living with HIV over 60 is growing
B.C. researchers simulated health and healthcare changes for people with HIV to the year 2034
More people with HIV are expected to have cardiovascular issues, cancer or other comorbidities
Thanks to the tremendous power of HIV treatment (antiretroviral therapy, ART), many people with HIV who are taking ART will live well into their senior years. As this population ages, they will become at risk for complications related to aging. What’s more, studies have found that people with HIV are at risk for earlier onset of age-related issues. Additionally, some studies have found that aging people with HIV are at risk for premature death from causes unrelated to HIV.
There are complex reasons for the earlier onset of age-related issues in people with HIV. In some cases, it may be due to excess inflammation caused by chronic HIV infection despite the use of ART and good adherence. In other cases, there may be psychosocial factors, such as isolation and lack of social support. Structural factors—such as access to housing, healthy food, healthcare and medicine—may also play a role. In addition, uncontrolled substance use may be a factor in the overall decline of health with age.
Johns Hopkins Researchers Awarded $41 Million to Continue Work Focused on People Living with HIV in the U.S.
August 20, 2026 - Johns Hopkins Bloomberg School of Public Health - Renewed NIH funding will support ongoing study of men and women living with HIV and create new centralized data and leadership centers
A team of Johns Hopkins researchers has been awarded three six-year grants totaling more than $41 million from the National Institutes of Health to continue investigating the occurrence and causes of chronic health conditions in men and women living with HIV in the U.S. through research underway for decades.
The new funding will support the MACS/WIHS Combined Cohort Study (MWCCS), formed in 2019 with the merger of two longitudinal studies: the Multicenter AIDS Cohort Study (MACS), an NIH-supported study of gay and bisexual men living with or without HIV that started in 1984, and the Women’s Interagency HIV Study (WIHS), a similar NIH-supported study of women that began in 1993.
The three NIH grants will fund a clinical research site, a data analysis and sharing site, and a leadership and coordination site.
Most Americans Have Not Seen Stories of People Living With HIV in Media in the Last Year: GLAAD Report
August 20, 2026 - ByMarc Malkin- Variety - GLAAD reported on Thursday that most Americans say they have not seen stories about people living with HIV in the media.
In its sixth annual State of HIV Stigma report, GLAAD says, “72% of Americans report they have not seen stories featuring real people living with HIV in the media over the past 12 months, an increase from 66% in 2024.”
Listen & read...
Bishop Rainey Cheeks, D.C. Pastor and HIV/AIDS Activist, Dies at 74
(AURN News) August 19, 2026 - By Clay Cane - The Black Chronicle - Bishop Kwabena Albert “Rainey” Cheeks, a longtime D.C. pastor and HIV/AIDS activist, died Aug. 11 at Georgetown University Hospital at age 74, according to the Washington Blade.
Read more...
UC San Diego Receives $12.3 Million Grant to Study the Intersection of HIV and Methamphetamine Use
August 17, 2026 - by Susanne Clara Bard - UC SAN DIEGO TODAY - UC San Diego - The study addresses a critical care gap by focusing on a vulnerable population historically excluded from research
A multidisciplinary approach integrating implementation science and brain research aims to create a scalable public health model for improving brain health by treating both substance use and HIV.
By replacing daily oral pills with long-acting injectables, the study seeks to improve medication adherence for participants with methamphetamine use disorder.
UC San Diego has received a $12.3 million, five-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to launch the Brain-Focused Research on Antiretrovirals and Methamphetamine (Brain-FRAMe) program, a multidisciplinary initiative focused on improving the clinical care and brain health of people with HIV who also have an active methamphetamine use disorder.
Methamphetamine use presents a critical public health challenge, as it significantly increases the risk of HIV infection and complicates the management of the virus.
A Day to Honor HIV Long-Term Survivors
August 17, 2026 - By Trent Straube - POZ - The commemoration was established in 2014.
Friday, June 5, marked HIV Long-Term Survivors Awareness Day (HLTSAD) 2026. The date coincides with a historical milestone in the history of the AIDS epidemic. On June 5, 1981—45 years ago—the Morbidity and Mortality Weekly Report (MMWR), a publication of the Centers for Disease Control and Prevention, first reported on cases of a mysterious illness affecting young gay men; the disease soon became known as AIDS, which is caused by untreated HIV.
Read more...
Family Portrait
August 17, 2026 - By Mark S. King - POZ - A long-term survivor, his husband and his brother build a home for the ages.
Read more...
Celebrating 23 Years of www.PositivelyPositive.ca: Creating HIV/AIDS Awareness
August 15, 2026 - By Bradford McIntyre - Celebrating 23 years of www.PositivelyPositive.ca. Long-term HIV survivor Bradford McIntyre shares a historic reflection dedicated to creating HIV/AIDS awareness, fighting stigma, and showcasing the global efforts working to end HIV and AIDS
August 15, 2026, marks the 23rd anniversary of the launch of my website: “Bradford McIntyre Positively Positive Living with HIV/AIDS” (www.PositivelyPositive.ca). Designed to create awareness around the many HIV and AIDS issues and promote messages of positive living with HIV, the website has grown from a modest 20-page site in 2003 into an internationally recognized information and resource hub. To date, this independent, ad-free website has reached 21,494,155 hits from 187 countries globally.
As the founder and operator living openly with the HIV virus since 1984, in 1994, he entered public advocacy by appearing on national television to combat the heavy burden of HIV stigma and discrimination. Nearly a decade later, he launched his website to create a visible face for the movement and provide global connection.
Australia’s fight against HIV is not over as new challenges disrupt progress
August 14, 2026 - By Jeremy Story Carter - ABC - Not long after Stephen Borg was diagnosed with HIV in 2007, he was given a warning that has remained lodged in his heart ever since.
Read more...
Canada’s military bars recruits with HIV from joining. A veteran is challenging the policy in court.
August 14, 2026 - By Rachel Aiello - CityNews - Advocates are calling on the federal government to do more as HIV infections in Canada see its largest increase in a two-year period. Sean Hosein, Science and Medicine Editor at Canadian AIDS Treatment Information Exchange explains.
Watch Video...
Long-acting therapies continue to gain momentum in HIV, says GlobalData
11 August 2026 - GlobalData - The next phase of competition in the HIV market will be defined not only by achieving viral suppression, but by improving treatment adherence, reducing medication burden and delivering more convenient treatment options, with long-acting therapies at the forefront, according to GlobalData, a leading intelligence and productivity platform.
GlobalData forecasts that the HIV market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) will grow from $26.4 billion in 2023 to $30.6 billion by 2033, with increased uptake of long-acting therapies representing a key driver of growth.
Findings presented at the 26th International AIDS Conference (AIDS 2026) included positive new data for ViiV Healthcare’s Cabenuva (cabotegravir/rilpivirine) among adolescents living with HIV.
Study: Triple-dose regimen may permanently clear HIV in infected newborns
Portland, Oregon, August 10, 2026 - By Erik Robinson - Oregon Health & Science University (OHSU) - OHSU-led discovery in animal model could advance quickly to clinical trials in people
Every year, more than 120,000 newborns worldwide contract HIV, a global health burden that requires lifelong treatment for millions of people — assuming they have access and can afford it.
New research led by Oregon Health & Science University suggests another possibility: a one-time regimen of therapies given to newborns within three days of birth to permanently clear the virus.
The research was published today in the journal Nature Microbiol
Adults Living with HIV Are at High Risk for Diabetes. Here’s Why
August 10, 2026 - By Levi Gadye - UCSF - University of California, San Francisco - UCSF study links scarred fat tissue to insulin resistance in people with HIV, even when they aren’t obese.
A new UC San Francisco study helps explain why people with HIV remain at elevated risk for type 2 diabetes despite effective suppression of the virus with modern medications.
To investigate, the team compared blood samples and fat biopsies of 46 people living with well-controlled HIV to those of 74 people without HIV. None of the participants were obese or had diabetes.
The researchers found that the people with HIV had more fibrosis, or scarring, in their fat tissues, and this was associated with insulin resistance — a key predictor of type 2 diabetes. The scarring was obvious in HIV patients no matter their body weight or the specific kinds of HIV medications they were taking.
Canada falling behind on funding HIV care as infections rise: experts
August 10, 2026 - CityNews - Advocates are calling on the federal government to do more as HIV infections in Canada see its largest increase in a two-year period. Sean Hosein, Science and Medicine Editor at Canadian AIDS Treatment Information Exchange explains.
Watch Video...
Sharon Stone and John Stamos to Be Honored at the Creative Coalition’s Humanitarian Awards (EXCLUSIVE)
August 10, 2026 - By Matt Minton - Variety - Additional honorees at the pre-Emmys event include Simran Baidwan, Cara Buono, Lisa Ann Walter and Mary Lou Belli.
Sharon Stone and John Stamos are set to be honored at The Creative Coalition’s Humanitarian Awards.
Read more...
‘We are living in reverse.’ Fragile HIV funding puts another strain on Kansas City’s safety net
August 10, 2026 - By Suzanne King - The Beacon - HIV health providers have already absorbed some cuts and fear more. They worry that gains made toward eliminating the virus are in jeopardy.
Roberto Archuleta was 21 years old in 1991 when he found out he was HIV-positive.
At the time, the only medications available to treat the virus were difficult to tolerate and often ineffective. Being diagnosed was commonly a death sentence — something Archuleta, then a hairstylist in Kansas City, witnessed too often.
Read more...
The Last Mile of Care: Community Health Workers in Lesotho
AUGUST 8, 2026 -The Borgen Project - For residents of Lesotho’s mountain districts, reaching a clinic means a walk of several hours across some parts of southern Africa’s highest terrain. This distance determines who receives treatment just as much as a shortage of treatment. Yet a growing network of community health workers in Lesotho is narrowing that gap, carrying Human Immunodeficiency Syndrome (HIV) treatment support, maternal care and disease monitoring directly into villages that the formal health system has struggled to reach.
A Health System Under Strain
Lesotho carries one of the heaviest HIV burdens in the world. An estimated 18.5% of adults ages 15 to 49 were living with HIV in 2023, and roughly 236,000 people 15 and older were on antiretroviral therapy that year, according to the U.S. Centers for Disease Control and Prevention (CDC). Tuberculosis compounds the crisis: an estimated 664 cases occurred per 100,000 people in 2023, and half of all Tuberculosis (TB) cases involved HIV coinfection, making continuous, coordinated care essential rather than optional.
Cutbacks in global aid could spark HIV epidemic resurgence
August 7, 2026 - By Heather Klein - THE WINNIPEG SUN - A new class of drugs called CD4 mimetics could be used to sensitise the immune system to HIV, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard last week.
It is becoming clear that broadly neutralising antibodies, whether infused as a drug or generated by a vaccine, may not be sufficient to cure HIV, or even to lead to long-term remission off antiretroviral therapy.
Read more...
Tumor-like tissue environments could hold clues to curing HIV
August 7, 2026 - Northwestern Now - Northwestern University - - Study microenvironment in animal models -
- Comparisons between virus and tumor microenvironment -
- Used novel molecular imaging and spatial transcriptomics -
The tissue microenvironments surrounding HIV-infected immune cells look a lot like those surrounding cancerous tumors, reports a new Northwestern University study.
The findings help explain why HIV has been so difficult to cure. Scientists found that viral reservoirs exist within tissue microenvironments that resemble immune-suppressive tumor microenvironments, suggesting that future HIV cure strategies may benefit from approaches traditionally used in cancer therapy.
The study was published Aug. 4 in the journal Frontiers in Immunology.
What China’s expanded funding for HIV/Aids in Africa means as US cuts health aid
7 August 2026 - By Jevans Nyabiage - South China Morning Post - Beijing backs local medicine manufacturing, with senior UN official voicing gratitude for ‘strong commitment to multilateralism’
China is expanding its role in the fight against HIV/Aids in Africa by funding new projects and backing local medicine manufacturing as part of its signature health initiative, the Health Silk Road.
Read more...
A new class of drugs could sharpen the body’s immune response to HIV
7 August 2026 - By Gus Cairns - The News Pakistan - Two Alberta infectious disease specialists have launched a national coalition aimed at preventing a resurgence of HIV infections as international funding cuts threaten decades of progress against the virus.
Dr. M. John Gill and Dr. Raynell Lang, both with the University of Calgary, have formed the Canadian Strategic Consortium to Address the Changing Policies and Environment of Global HIV Care, known as CanSCAPE-HIV.
Read more...
Liver disease and HIV: Study reveals major gaps in liver fibrosis screening and offers a promising solution
August 6, 2026 - McGill University Health Centre - Current liver fibrosis screening misses many cases in people living with HIV and could be improved with a new tool developed by researchers at The Institute.
Thanks to antiretroviral therapy and improved control of viral hepatitis (HBV and HCV), people living with HIV generally live longer and healthier lives. However, liver disease remains common in this population and is one of the leading causes of death.
A large international study found that among people living with HIV, liver fibrosis, a build-up of scar tissue in the liver that can lead to permanent damage, is common, often has no symptoms and is frequently missed by the FIB-4 blood test, the first-line screening tool used in clinical practice. Led by Dr. Giada Sebastiani at the Research Institute of the McGill University Health Centre (The Institute), the study introduces the FIB-HIV score, a new tool that could improve the identification of people at risk of liver fibrosis by incorporating metabolic and HIV-specific factors. Effective detection of liver fibrosis is critical to ensure patients receive appropriate care.
Returning to HIV care does not erase the effects of treatment interruption, studies show
6 August 2026 - By Edith Magak - aidsmap - CD4 counts fall much faster than they recover, increasing the harms of cycling in and out of care
People with HIV in South Africa are ten times more likely to develop tuberculosis while interrupting treatment than while taking it, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard last week. Even after resuming treatment and achieving viral suppression, their risk stayed 50% higher.
Read more...
‘25,000 HIV/Aids deaths recorded since first case in 1987’
Islamabad: August 06, 2026 - By M. Waqar Bhatti - The News Pakistan - More than 25,000 peop1le, including hundreds of children, have officially died of HIV infection and Aids-related illnesses in Pakistan since the country’s first Aids case was reported in Lahore in 1987, data compiled by the federal and provincial health departments reveal.
Read more...
Canadian doctors form consortium to prevent potential ‘resurgence of the HIV epidemic’
Aug 05, 2026 - By Karina Zapata - CBC - Group calls on governments to better educate newcomers on available HIV resources
Two Calgary doctors worry global cuts to HIV programs could lead to a potential “resurgence of the HIV epidemic,” which could have implications across Canada, including in Alberta.
They’ve formed a national consortium to come up with preventative solutions before it’s too late, named the Canadian Strategic Consortium to Address the Changing Policies and Environment of Global HIV Care (CanSCAPE-HIV).
Listen & Read more...
Gareth Thomas opens up on life with HIV after admitting husband is shunned
05 Aug 2026 - By Maria Ortega and Tom Sunderland - Wales Online - Welsh sporting icon Gareth Thomas has found new ways to savour his life despite his HIV diagnosis. However, the former Cardiff and Toulouse star has commented in the past about how the condition has resulted in repercussions for his loved ones.
Read more...
Russia Says Its HIV Rates Are Falling. Experts Aren’t So Sure.
August 5, 2026 - By Maria Ortega and Tom Sunderland - The Moscow Times - Four years ago, while hospitalized with Covid-19, St. Petersburg singer Ksenia Aleksandrova was unexpectedly diagnosed with HIV.
Known by her stage name Neksusha, the 23-year-old Aleksandrova has built a devoted online following, with around 90,000 subscribers on YouTube and more than 213,000 monthly listeners on Spotify. Despite the persistent stigma that surrounds HIV, she decided to publicly disclose her diagnosis in an effort to raise awareness about the illness.
Read more...
Friends for Life Bike Rally rolls into Kingston while raising funds for HIV/AIDS services
August 4, 2026 - Jesse Reynolds - Global News - A sea of red rolled into Kingston today. The Friends for Life Bike Rally is halfway through its six-day, 600-kilometre journey from Toronto to Montreal. This year, riders are aiming to raise 1.9 million dollars for HIV and AIDS support services. Jesse Reynolds has more.
Watch Video...
Once-weekly HIV therapy may offer alternative to daily pills
August 4, 2026 - By Laine Bergeson - CIDRAP - Center for Infectious Disease Research & Policy - University of Minnesota - A once-weekly oral HIV treatment maintained viral suppression as effectively as a standard once-daily regimen in a phase 3 clinical trial, offering a potential new treatment option for people living with HIV.
The randomized, double-blind trial, published in the New England Journal of Medicine last week, looked at a once-weekly combination tablet containing islatravir and lenacapavir in adults whose HIV had remained suppressed for at least six months while taking the daily regimen bictegravir–emtricitabine–tenofovir alafenamide.
Enhanced access to diagnostic screening improves care for advanced HIV
4 August 2026 - By Keith Alcorn - aidsmap - Two studies presented at the 26th International AIDS Conference (AIDS 2026) last week show that wider access to diagnostic testing and consistent implementation of screening guidance could each improve the diagnosis of opportunistic infections in people with low CD4 counts.
World Health Organization (WHO) guidance recommends that all people with HIV should receive a CD4 cell test at diagnosis or when re-engaging with care after a treatment gap.
Read more...
New HIV infections in Canada are rising. Advocates say years of progress are at risk
Aug 01, 2026 - By Tashauna Reid - CBC - New HIV infections increased by 23% in 2024, Public Health Agency of Canada says
Dr. Julio Montaner has spent decades in the fight against HIV but says he feels years of progress slipping away.
“I am very worried about what’s coming our way,” said Montaner, executive director and physician-in-chief at the BC Centre for Excellence in HIV/AIDS in Vancouver, the largest HIV/AIDS research and treatment facility in Canada.
Listen & Read more...
For more HIV and AIDS News visit…
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
Back to Top
HIV/AIDS News
|
